GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Change In Receivables

Novelion Therapeutics (STU:QLTA) Change In Receivables : €-9.5 Mil (TTM As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics Change In Receivables?

Novelion Therapeutics's change in receivables for the quarter that ended in Mar. 2019 was €1.7 Mil. It means Novelion Therapeutics's Accounts Receivable declined by €1.7 Mil from Dec. 2018 to Mar. 2019 .

Novelion Therapeutics's change in receivables for the fiscal year that ended in Dec. 2018 was €-5.9 Mil. It means Novelion Therapeutics's Accounts Receivable increased by €5.9 Mil from Dec. 2017 to Dec. 2018 .

Novelion Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2019 was €23.8 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Novelion Therapeutics's Days Sales Outstanding for the three months ended in Mar. 2019 was 76.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Novelion Therapeutics's liquidation value for the three months ended in Mar. 2019 was €-338.3 Mil.

Novelion Therapeutics Change In Receivables Historical Data

The historical data trend for Novelion Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Change In Receivables Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.01 -0.85 -10.86 -5.93

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.97 -2.00 -2.77 -6.42 1.70

Novelion Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics  (STU:QLTA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Novelion Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2019 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=23.784/28.497*91
=76.16

2. In Ben Graham's calculation of liquidation value, Novelion Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Novelion Therapeutics's liquidation value for the quarter that ended in Mar. 2019 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=45.948-408.046+0.75 * 23.784+0.5 * 11.865
=-338.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (STU:QLTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Change In Receivables
Comparable Companies
DFFN TSXV:KLY TSXV:QPT ASX:PTX ROCO:4197 XSAT:WNT PTIX IST:RTALB TROV NOVN MATN LSE:TRX ASX:NYR ATOS TSXV:BCT JAGX TSX:CTX ROCO:6744 ACHV EMBI
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Website
http://www.novelion.com
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.